Integrated In Silico Approach Discovery of β-Caryophyllene from Piper crocatum Ruiz & Pav. as an Antidiabetic Candidate
Abstract
Type 2 diabetes mellitus (T2DM) remains a significant global health challenge, responsible for more than 90% of all diagnosed diabetes cases worldwide. The progression of T2DM is primarily driven by insulin resistance and progressive pancreatic β-cell dysfunction, both of which contribute to various metabolic complications. Metformin is widely used as a first-line antidiabetic drug. However, its long-term use is associated with gastrointestinal disturbances, lactic acidosis, and vitamin B12 deficiency. These limitations highlight the need for safer and more effective therapeutic alternatives. β-caryophyllene, a sesquiterpene compound derived from the stem extract of Piper crocatum Ruiz & Pav., has demonstrated antioxidant, anti-inflammatory, and antilipidemic properties that may support its potential as an antidiabetic agent. This study evaluated the pharmacological potential of β-caryophyllene as an antidiabetic agent through an in silico approach. The analysis included drug-likeness assessment via Lipinski’s Rule of Five, ADMET profiles, network pharmacology, such as KEGG pathway and GO, inhibitory activity prediction using SVM regression in DataWarrior, and molecular docking through AutoDockTools and BIOVIA Discovery Studio, with metformin used as a reference standard. β-caryophyllene fully complies with Lipinski’s Rule of Five, indicating good drug-likeness and potential for oral bioavailability. The IC50 prediction results indicated that β-caryophyllene exhibited…
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.